NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $58.50
  • Forecasted Upside: 5.23 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$55.59
▼ -0.15 (-0.27%)
1 month | 3 months | 12 months
Get New Rocket Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCKT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$58.50
▲ +5.23% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $58.50, with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 5.23% upside from the last price of $55.59.
Buy
The current consensus among 14 investment analysts is to buy stock in Rocket Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021Stifel NicolausInitiated CoverageBuy$64.00Low
i
2/25/2021Needham & Company LLCInitiated CoverageBuy$75.00High
i
2/18/2021Needham & Company LLCInitiated CoverageBuy$75.00Medium
i
1/4/2021Piper SandlerBoost Price Target$60.00 ➝ $80.00N/A
i
12/15/2020UBS GroupInitiated CoverageBuy$75.00Medium
i
12/10/2020Evercore ISIBoost Price TargetOutperform$65.00 ➝ $100.00High
i
12/8/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $46.00High
i
Rating by Geulah Livshits at Chardan Capital
12/8/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $50.00High
i
12/8/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
11/23/2020JPMorgan Chase & Co.Boost Price TargetOverweight$38.00 ➝ $43.00High
i
Rating by Eric Joseph at JPMorgan Chase & Co.
11/4/2020SVB LeerinkReiterated RatingOutperformMedium
i
Rating by M. Foroohar at SVB Leerink LLC
10/16/2020Lifesci CapitalReiterated RatingOutperformLow
i
Rating by P. Dolezal at Lifesci Capital
10/16/2020Chardan CapitalBoost Price TargetBuy$33.00 ➝ $35.00High
i
Rating by Geulah Livshits at Chardan Capital
9/22/2020OppenheimerLower Price TargetOutperform$43.00 ➝ $33.00Low
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
8/9/2020CowenReiterated RatingBuyMedium
i
8/5/2020Ci CapitalReiterated RatingBuy$35.00High
i
7/13/2020OppenheimerReiterated RatingBuy$43.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
7/13/2020Chardan CapitalReiterated RatingBuy$33.00High
i
Rating by Geulah Livshits at Chardan Capital
7/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
i
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
i
6/1/2020OppenheimerInitiated CoverageBuyMedium
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
5/6/2020William BlairReiterated RatingBuyMedium
i
3/11/2020Chardan CapitalReiterated RatingBuy$33.00High
i
Rating by Geulah Livshits at Chardan Capital
3/5/2020William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
3/5/2020Chardan CapitalReiterated RatingBuy$33.00Low
i
Rating by Geulah Livshits at Chardan Capital
12/9/2019OppenheimerBoost Price TargetOutperform$36.00 ➝ $42.00Low
i
12/6/2019Chardan CapitalReiterated RatingBuy$30.00Low
i
Rating by Geulah Livshits at Chardan Capital
12/6/2019Robert W. BairdBoost Price TargetOutperform$30.00 ➝ $41.00High
i
11/17/2019CowenReiterated RatingBuyLow
i
11/7/2019CowenReiterated RatingBuyHigh
i
11/5/2019Chardan CapitalInitiated CoverageBuy$30.00High
i
Rating by Y. Livshits at Chardan Capital
9/26/2019Piper Jaffray CompaniesInitiated CoverageOverweightHigh
i
9/10/2019William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
9/4/2019William BlairReiterated RatingBuyLow
i
Rating by Raju Prasad at William Blair
8/22/2019William BlairReiterated RatingBuyLow
i
8/13/2019OppenheimerLower Price TargetOutperform$39.00 ➝ $37.00Medium
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
5/8/2019CowenReiterated RatingBuyLow
i
5/1/2019William BlairReiterated RatingBuyMedium
i
Rating by Raju Prasad at William Blair
4/22/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformHigh
i
4/9/2019William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
3/19/2019OppenheimerSet Price TargetBuy$39.00High
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
3/15/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$27.00High
i
3/5/2019OppenheimerSet Price TargetBuy$39.00High
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
2/26/2019CowenInitiated CoverageOutperformLow
i
2/5/2019CIBCInitiated CoverageOutperform ➝ Outperform$39.00Medium
i
2/5/2019OppenheimerInitiated CoverageOutperform$39.00 ➝ $39.00Low
i
11/27/2018SVB LeerinkInitiated CoverageOutperform$22.00High
i
Rating by M. Foroohar at SVB Leerink LLC
11/27/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
11/7/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
10/18/2018William BlairReiterated RatingBuyMedium
i
Rating by Raju Prasad at William Blair
9/13/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$30.00High
i
8/8/2018William BlairInitiated CoverageBuyMedium
i
Rating by R. Prasad at William Blair
7/10/2018William BlairInitiated CoverageOutperformHigh
i
Rating by R. Prasad at William Blair
5/11/2018CowenReiterated RatingBuyHigh
i
3/9/2018CowenInitiated CoverageOutperformMedium
i
1/30/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$27.00High
i
7/12/2017Canaccord GenuityDowngradeBuy ➝ HoldMedium
i
Rating by Dewey Steadman at Canaccord Genuity
7/11/2017HC WainwrightDowngradeBuy ➝ Neutral$2.00High
i
Rating by Corey Davis at HC Wainwright
6/26/2017Canaccord GenuitySet Price TargetBuy$3.00N/A
i
Rating by Dewey Steadman at Canaccord Genuity
5/12/2017HC WainwrightReiterated RatingBuy$7.00Low
i
Rating by Corey Davis at HC Wainwright
4/12/2017HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Corey Davis at HC Wainwright
3/17/2017HC WainwrightReiterated RatingBuy$7.00Low
i
Rating by Corey Davis at HC Wainwright
3/16/2017Canaccord GenuitySet Price TargetBuy$3.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
1/4/2017HC WainwrightReiterated RatingBuy$7.00N/A
i
Rating by Corey Davis at HC Wainwright
1/3/2017Canaccord GenuitySet Price TargetBuy$9.00N/A
i
Rating by Dewey Steadman at Canaccord Genuity
1/3/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$3.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
12/20/2016Canaccord GenuitySet Price TargetBuy$20.00N/A
i
12/1/2016Roth CapitalInitiated CoverageBuy$10.00N/A
i
Rating by S. Yaniv at Roth Capital
11/14/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by corey davis at HC Wainwright
9/20/2016HC WainwrightInitiated CoverageBuy$22.00N/A
i
Rating by C. Davis at HC Wainwright
8/16/2016Piper Jaffray CompaniesReiterated RatingBuy$24.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
7/20/2016Piper Jaffray CompaniesSet Price TargetBuy$29.00N/A
i
Rating by ">Joshua Schimmer at Piper Jaffray Companies
5/14/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
5/12/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
(Data available from 3/2/2016 forward)
Rocket Pharmaceuticals logo
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $55.59
$54.62
$57.60

50 Day Range

MA: $56.86
$51.85
$65.91

52 Week Range

Now: $55.59
$9.01
$67.48

Volume

58,350 shs

Average Volume

472,063 shs

Market Capitalization

$3.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Rocket Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rocket Pharmaceuticals in the last year: Bank of America Co., Chardan Capital, Ci Capital, Cowen Inc, Evercore ISI, JPMorgan Chase & Co., Lifesci Capital, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for RCKT.

What is the current price target for Rocket Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Rocket Pharmaceuticals in the last year. Their average twelve-month price target is $57.89, suggesting a possible upside of 3.9%. Evercore ISI has the highest price target set, predicting RCKT will reach $100.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $33.00 for Rocket Pharmaceuticals in the next year.
View the latest price targets for RCKT.

What is the current consensus analyst rating for Rocket Pharmaceuticals?

Rocket Pharmaceuticals currently has 1 hold rating and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCKT will outperform the market and that investors should add to their positions of Rocket Pharmaceuticals.
View the latest ratings for RCKT.

What other companies compete with Rocket Pharmaceuticals?

How do I contact Rocket Pharmaceuticals' investor relations team?

Rocket Pharmaceuticals' physical mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company's listed phone number is 646-440-9100 and its investor relations email address is [email protected] The official website for Rocket Pharmaceuticals is www.rocketpharma.com.